Novel Mutations in the CYP7B1 Gene Cause Hereditary Spastic Paraplegia
Li Cao,Qing-Zhou Fei,Weiguo Tang,Jianrong Liu,Lan Zheng,Qin Xiao,Songbin He,Yi Fu,Shengdi Chen
DOI: https://doi.org/10.1002/mds.23466
IF: 9.698
2011-01-01
Movement Disorders
Abstract:Anecdotally, clinicians have known that Parkinson’s disease (PD) patients may report alleviation of what appears to be pain arising from peripheral structures, in response to dopaminergic medication. Drs. Nebe and Ebersbach contribute to the small literature documenting this phenomenon. They report that 14 of 15 PD patients with motor fluctuations experience less intense pain (of various types, the majority with degenerative osteoarticular changes) after administration of a supra-threshold dose of levodopa (L-dopa). So-called ‘‘central’’ pain has been reported in various studies to account for as little as 0–10% of pain/sensory complaints in PD; however, central mechanisms underlying primary PD pain are also likely to mediate pain arising from peripheral structures. In a recent study, 50 PD outpatients were carefully classified according to L-dopa response (stable responders, fluctuators, and patients with dyskinesia). We reported a marked improvement in experimentally evoked pain responses after L-dopa administration in patients with dyskinesia, but not in stable responders. We would like to expand on our investigations of the response of spontaneous pain to L-dopa, which were previously reported in brief only. After L-dopa challenge, we found a 6-point reduction in Gracely pain scores (range of scale 0– 20) for spontaneous pain that was not clearly nociceptive in origin in 21 patients. Taking patients who endorsed Gracely scores 6 in the off-medication state as the denominator, the proportion of patients whose pain improved with L-dopa was 50% (2 of 4), 89% (8 of 9), and 100% (11 of 11) for the stable responder, fluctuator, and dyskinetic groups, respectively (P 1⁄4 0.029, Fisher’s Exact Test). The commonest complaint was shoulder/upper limb pain (9 of 21 cases; in all but one patient, this pain was ipsilateral to the side of worse Parkinsonism). This was followed by dystonic leg pain (5 patients), neck pain (2 patients), low back pain (2 patients), thigh pain (1 patient), rib pain (1 patient), and painful restless legs syndrome (1 patient). Thus, our results provide support for the findings of Nebe and Ebersbach, at least with respect to patients with motor fluctuations and/or dyskinesia. Interestingly, another patient (a stable responder), who had rib pain from a fall 5 weeks prior (i.e., clearly nociceptive pain), also experienced significant improvement after L-dopa (scores for pain intensity and unpleasantness reduced from 13 and 9 to 1 and 1). We also prospectively administered the McGill pain questionnaire (in the off-medication state) to 28 patients reporting any pain (regardless of cause and severity) on the day of the L-dopa challenge. In our cohort, only 32% (9 of 28) of patients endorsed both, or either of the terms ‘‘fearful’’ and/ or ‘‘punishing-cruel’’ (i.e., similar to Nebe and Ebersbach’s historical non-PD cohort), with median/mean scores of 1/1.3 and 2/1.8, respectively, in patients who endorsed these terms (0 1⁄4 none, 1 1⁄4 mild, 2 1⁄4 moderate, 3 1⁄4 severe). Thus, these data do not support the authors’ finding that PD patients frequently (in 87% of their cases) describe pain in terms related to fear and punishment. We observe that while PD-related pain can be strongly influenced by the effects of dopaminergic medication, a common experience in clinical practice is for pain not to improve, despite optimization of dopaminergic medication. The authors suggest that the impact of L-dopa on pain may be underestimated by retrospective evaluations, but other factors may also need to be considered. For instance, pain responses are highly susceptible to placebo, and none of the published experimental studies (including ours) have investigated the effects of L-dopa versus placebo on pain. Moreover, it was recently reported that the highest rates of a placebo response in treatment trials may occur in PD patients manifesting motor response complications. A more complex relationship may exist between pain and dopaminergic treatment effects, and PD-related pain is likely to be multifactorial in origin, with varying degrees of contribution from peripheral and central mechanisms. A range of nondopaminergic structures involved in the neurodegenerative process of PD, in the spinal cord, brainstem, diencephalon, and limbic system, are also likely to mediate pain processing in PD. In light of these considerations, while we agree with Nebe and Ebersbach that modification of dopaminergic therapy should underpin treatment of PD patients presenting with pain, clinicians should be ready to adopt alternative measures to augment this approach. We are concerned that PDrelated pain is currently already under-treated compared with pain in non-PD subjects, despite PD patients’ report of greater pain intensity and impact on quality of life. Lim: Research project: conception, organization, and. execution; statistical analysis: Design, execution, and review and critique; Manuscript: Writing of the first draft and review and critique. Farrell: research project: organization and execution; Statistical analysis execution and review and critique of the manuscript. Evans: Research project: conception, organization, and execution; review and critique of statistical analysis and the manuscript.